Top stories

Kovacin’s India Biotech Emergency Use has also received approval from a panel of experts

An expert committee on Covid-19 of the Central Drugs Standards Control Organization (CDSCO) on Saturday recommended the approval of the India-developed India Biotech’s anti-coronary virus vaccine ‘Kovacin’ for limited emergency use in India, citing some regulatory provisions, sources said.

In collaboration with the Indian Council of Medical Research (ICMR), India Biotech has developed covaxin domestically. The vaccine from a Hyderabad-based pharmaceutical firm was reconsidered on Saturday after a submission was handed over to the CDSC’s Committee of Experts (SEC) on Covid-19 for emergency use, sources said.

In December, India Biotech filed an application with the Comptroller General of India Pharmaceuticals (DCGI) for approval of the domestically developed covacin vaccine. The SEC on Friday recommended the approval of the Oxford-Astrageneca anti-coronavirus vaccine ‘Covishield’ for emergency use in India. Now the Drug Controller General of India (DCGI) will give final approval to both vaccines.

The committee recommended the emergency use of the Covid-19 vaccine in Oxford, enforcing certain regulatory rules, saying the vaccine was intended to increase immunity in people 18 years of age or older to prevent the disease. It is and should be given in two doses by intramuscular injection at intervals of four to six weeks.

Clinical trials of six coronary vaccines are currently underway in India. These include covishield and covaxin. Covishield is an ostroxy vaccine, developed by Astragenica and Serum Institute of India, Pune. Kovaxin is a desi vaccine developed in collaboration with the Indian Biotech of Indian Medical Research Council.

In addition to these two, Cadillac Health Care Limited of Ahmedabad is developing in collaboration with Zykovi-D Biotechnology Department. Also NVX-Covey 2373 is developing Serum Institute in collaboration with NovaMax. There are two more vaccines, one of which has been developed by Biological E Limited of Hyderabad in association with MIT, USA. The second HDT has been developed by Pune-based Genova Biopharmaceuticals Limited in collaboration with USA.


Show More

Related Articles

Leave a Reply

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker